TG Therapeutics jumps after second consecutive quarterly beat [Seeking Alpha]
TG Therapeutics, Inc. (TGTX)
Last tg therapeutics, inc. earnings: 11/12 07:34 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.tgtherapeutics.com
Company Research
Source: Seeking Alpha
The Morrisville, North Carolina-based company reported ~$44.0M in net revenue in Q4, up from $80K in the prior-year period, compared to ~$40.1M in FactSet Consensus. Its newly launched multiple sclerosis therapy, Briumvi, boosted the top line, adding $39.9M in net product sales in Q4 with 3,200 prescriptions received from about 640 healthcare providers since its launch, compared to 2,200 prescriptions as of Q3. The FDA authorized the anti-CD20 monoclonal antibody in late 2022, leading to its market rollout in January 2023. The company swung to a net profit of $12.7M in 2023 after recording $198.4M of net loss in the prior year as net product sales from Briumvi reached $88.8M last year. Looking ahead, TG Therapeutics ( TGTX ) projects net product sales of Briumvi to reach $220M-$260M this year. Recommended For You Recommended For You About TGTX Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
TGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TGTX alerts
High impacting TG Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TGTX
News
- TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewswire
- TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business UpdateGlobeNewswire
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $39.00 price target on the stock.MarketBeat
- TG Therapeutics, Inc. (NASDAQ: TGTX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $25.00 price target on the stock.MarketBeat
TGTX
Earnings
- 5/1/24 - Miss
TGTX
Sec Filings
- 5/1/24 - Form 8-K
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- TGTX's page on the SEC website